Chiang Mai Ram Medical Business PCL

Chiang Mai Ram Medical Business PCL maintains a debt-to-equity ratio of 0.9, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 0.37, suggesting potential challenges in meeting short-term obligations. The return on equity of 0.0184 and return on assets of 0.0064 indicate that the company is generating relatively low returns compared to its equity and asset base.

The company's profitability is reflected in its net income of 71,803,040 THB, but its operating income of 186,859,330 THB suggests that operational efficiency is a key factor in its financial performance. The gross profit of 373,978,140 THB indicates that the company is managing its production costs effectively. However, the company's returns are below the industry median for healthcare facilities and services, indicating a need for improvement in operational efficiency and cost management.

The company's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification reported. This concentration may pose a risk if the pharmaceutical market experiences volatility or regulatory changes. The company's revenue of 1,430,890,730 THB is a key indicator of its market position, but the lack of segment-specific data limits a more detailed analysis.

The company's growth trajectory is modest, with a revenue of 1,430,890,730 THB in the latest reporting period. The capital expenditure of -227,366,890 THB indicates a reduction in investment, which may affect long-term growth potential. The free cash flow of 123,229,770 THB suggests that the company has some flexibility in funding operations and investments, but the negative net cash position after subtracting total debt highlights liquidity constraints.

The company's risk profile is characterized by medium liquidity risk and low dilution potential. The key risk flag of negative net cash after subtracting total debt indicates that the company may need to secure additional financing to maintain its operations. The dilution potential is low, suggesting that the company is not likely to issue additional shares in the near term.

Recent events, including the latest financial filings and transcripts, indicate that the company is maintaining a stable financial position despite the challenges in the healthcare sector. The company's operating cash flow of 745,807,310 THB is a positive sign, but the negative net cash position remains a concern.

Net margin of 5.0% outperforms the 4.2% industry median, demonstrating strong profitability relative to healthcare peers.

Revenue grew at a 20.6% CAGR over four years, showing consistent top-line expansion despite recent volatility.

Cash conversion ratio of 10.39 is best-in-class, vastly superior to the 1.35 sector median.

Dilution risk is assessed as low, providing relative stability for existing shareholders compared to higher-risk peers.

Debt-to-equity ratio of 0.9 is in the bottom quartile, reflecting high leverage compared to the 0.32 median.

Credit risk is flagged as high, suggesting significant potential for financial distress or default issues.

Revenue THB 1.30B, −9,1% YoY; Operating income −51,8% YoY.

• ▍Revenue THB 1.30B, −9,1% YoY
• ▍Operating income −51,8% YoY
• ▍Net income −211,3% YoY
• ▍Free cash flow −566,5% YoY
• ▍Net margin -6.1%

Revenue THB 1.22B; Operating income THB 64.7M.

• ▍Revenue THB 1.22B
• ▍Operating income THB 64.7M
• ▍Net margin 2.0%

Revenue THB 1.32B; Operating income THB 140.0M.

• ▍Revenue THB 1.32B
• ▍Operating income THB 140.0M
• ▍Net margin 3.7%

Revenue THB 1.25B; Operating income -THB 7.8M.

• ▍Revenue THB 1.25B
• ▍Operating income -THB 7.8M
• ▍Net margin -4.8%

Revenue THB 2.50B, −52,8% YoY; Operating income +450,2% YoY.

• ▍Revenue THB 2.50B, −52,8% YoY
• ▍Operating income +450,2% YoY
• ▍Net income +1 774,2% YoY
• ▍Free cash flow +888,5% YoY
• ▍Net margin 98.0%